Skip to main content
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ATNM ISIN · US00507W2061 LEI · 549300LCY1NZSXCQDT45 US Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2013-01-28 Capital/Financing Update
Country US United States of America
Listing US ATNM

About Actinium Pharmaceuticals, Inc.

https://www.actiniumpharma.com/

Actinium Pharmaceuticals, Inc. is a clinical-stage company focused on developing targeted radiotherapies for patients with cancers lacking effective treatment options. The company's platform utilizes potent radioisotopes, such as the alpha-emitter Actinium-225, conjugated to monoclonal antibodies to precisely deliver radiation to cancer cells. Its clinical pipeline addresses hematologic malignancies and solid tumors. Key programs include Iomab-B, a targeted conditioning agent for bone marrow transplant in patients with relapsed or refractory Acute Myeloid Leukemia (AML), and Actimab-A, a CD33-targeting therapy for AML. The company is also advancing ATNM-400, a novel non-PSMA therapeutic for prostate cancer, and developing its proprietary Actinium-225 manufacturing technology and infrastructure.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the completion of a private offering of equity securities, details about the reverse merger transaction, and forward-looking statements. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript, proxy, or governance document. The focus is on a capital raising event and related disclosures. Therefore, the filing best fits the category of Capital/Financing Update (CAP). The document length is 6126 characters, which is sufficient to contain substantive information rather than just an announcement of a report. Hence, the classification is CAP with high confidence.
2013-01-28 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 2) filed with the SEC, which is a Current Report. It details a material transaction involving a share exchange and acquisition, changes in control, changes in directors and officers, and other related corporate events. It includes sections such as Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.02 (Unregistered Sales of Equity Securities), Item 4.01 (Changes in Registrant’s Certifying Accountant), Item 5.01 (Changes in Control), Item 5.02 (Departure and Appointment of Directors and Officers), and others. It also references audited and unaudited financial statements as exhibits but does not itself contain full financial statements or detailed financial analysis. The document is a regulatory filing reporting significant corporate events and changes rather than a full annual or quarterly report, earnings release, or other specific report type. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other categories.
2013-01-28 English
PRIMARY DOCUMENT
Director's Dealing
2013-01-18 English
SCHEDULE 13D
Major Shareholding Notification
2013-01-18 English
Regulatory Filings 2013
Regulatory Filings
2013-01-14 English
PRIMARY DOCUMENT
Director's Dealing
2013-01-07 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.